Genomictree 228760.KQ · KRW

Its shares trade on KOSDAQ under the ticker 228760.KQ. It has been listed since 19 July 2016. In the fiscal year to 31 December 2025, it reported revenue of ₩3.76bn and a net loss of ₩8.99bn. At that date it held total assets of ₩120.76bn and shareholders' equity of ₩115.07bn.

Genomictree, Inc. engages in the development and supply of diagnostic products for cancer screening and prognosis. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2016-07-19. The firm is involved in conducting of genomic analysis using microarrays and next generation sequencing analysis. In addition, the Company is conducting clinical trials for molecular diagnostic products. Molecular diagnostic products include cancer molecular diagnostic products and molecular genetic diagnostic products. Cancer molecular diagnostic products include molecular diagnostic products for colorectal cancer, bladder cancer, lung cancer, stomach cancer, cervical cancer. Molecular genetic diagnostic products include epidermal growth factor receptor (EGFR) mutation diagnosis, as well as human papilloma virus (HPV) diagnostic products.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Seong Hwan AhnChief Executive Officer, Director, since 2000
• Mr. Hong Seon LeeChief Financial Officer, Assistant Managing Director
• Mr. Chi Wang YoonVice President, Director, since 2000
• Mr. Tae Jeong OhManaging Director, since 2001
• Mr. Yong Wun LeeAssistant Managing Director
• Mr. Jik Yeol YooInternal Auditor
• Mr. Dong Jun JungNon-Executive Independent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.